Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $80.60.
Several brokerages have weighed in on TECH. Benchmark reaffirmed a “buy” rating and set a $95.00 price target on shares of Bio-Techne in a research report on Tuesday, August 13th. Royal Bank of Canada reduced their price target on Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating for the company in a research report on Thursday, August 8th. Finally, Robert W. Baird lifted their price objective on shares of Bio-Techne from $81.00 to $82.00 and gave the company an “outperform” rating in a report on Thursday, August 8th.
Check Out Our Latest Stock Report on Bio-Techne
Institutional Investors Weigh In On Bio-Techne
Bio-Techne Price Performance
Shares of TECH opened at $73.36 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.87 and a quick ratio of 2.75. The company’s fifty day moving average price is $74.35 and its 200-day moving average price is $74.36. Bio-Techne has a 1-year low of $51.79 and a 1-year high of $85.57. The firm has a market capitalization of $11.64 billion, a PE ratio of 70.54, a price-to-earnings-growth ratio of 5.27 and a beta of 1.27.
Bio-Techne (NASDAQ:TECH – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.49 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.49. Bio-Techne had a return on equity of 12.88% and a net margin of 14.50%. The business had revenue of $306.10 million for the quarter, compared to analyst estimates of $306.49 million. During the same period in the prior year, the company earned $0.56 earnings per share. The company’s revenue was up 1.6% on a year-over-year basis. On average, equities research analysts predict that Bio-Techne will post 1.7 EPS for the current year.
Bio-Techne Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Monday, August 19th were given a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a dividend yield of 0.44%. The ex-dividend date was Monday, August 19th. Bio-Techne’s payout ratio is presently 23.08%.
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Featured Articles
- Five stocks we like better than Bio-Techne
- Insider Buying Explained: What Investors Need to Know
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Investing In Automotive Stocks
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Using the MarketBeat Dividend Yield Calculator
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.